1. Signaling Pathways
  2. GPCR/G Protein
    MAPK/ERK Pathway
  3. Ras

Ras

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146533
    KRAS inhibitor-12
    Inhibitor
    KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC50 of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC50s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-12
  • HY-143606
    KRAS G12D inhibitor 12
    Inhibitor
    KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134).
    KRAS G12D inhibitor 12
  • HY-144211
    SOS1-IN-7
    Inhibitor
    SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
    SOS1-IN-7
  • HY-142948
    KRAS G12C inhibitor 46
    Inhibitor
    KRAS G12C inhibitor 46 (compound WX003) is a potent KRAS G12C inhibitor.
    KRAS G12C inhibitor 46
  • HY-162441
    pan-KRAS-IN-8
    Inhibitor
    pan-KRAS-IN-8 (Compound 38) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.07 and 0.18 nM, respectively.
    pan-KRAS-IN-8
  • HY-161177
    PROTAC KRAS G12D degrader 2
    Inhibitor
    PROTAC KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPro). Protac KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPRO). The PROTAC molecule is designed by partially coupling a GC-376-based dipeptidyl 3CLPro ligand with pomadomide via a piperazine-piperidine linker.
    PROTAC KRAS G12D degrader 2
  • HY-158703
    KRAS G12D inhibitor 24
    Inhibitor
    KRAS G12D inhibitor 24 (compound 103) is a potent inhibitor of KRAS G12D, with the IC50 of 0.004 μM. KRAS G12D inhibitor 24 has oral bioactivity.
    KRAS G12D inhibitor 24
  • HY-153461
    KRAS G12C inhibitor 58
    Inhibitor
    KRAS G12C inhibitor 58 is a KRAS G12C inhibitor, used in cancer research.
    KRAS G12C inhibitor 58
  • HY-161173
    PROTAC SOS1 degrader-5
    Inhibitor
    PROTAC SOS1 degrader-5 (compound 4) is a potent PROTAC SOS1 degrader, with the DC50 of 13 nM. PROTAC SOS1 degrader-5 strongly inhibits NCI-H358 cells proliferation with an IC50 of 5 nM.
    PROTAC SOS1 degrader-5
  • HY-162446
    pan-KRAS-IN-13
    Inhibitor
    pan-KRAS-IN-13 (compound 2) is a potent inhibitor of KRAS, with IC50s of 2.75 nM and 2.89 nM for G12D and G12V, respectively
    pan-KRAS-IN-13
  • HY-164350
    KRAS inhibitor-27
    Inhibitor
    KRAS inhibitor-27 (Compound 15h) is the inhibitor for KRAS. KRAS inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC50 of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC50 in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway.
    KRAS inhibitor-27
  • HY-134264
    8-Br-2'-O-Me-cAMP
    Activator
    8-Br-2'-O-Me-cAMP is an analogue of the signal molecule cyclic AMP (cAMP). 8-Br-2'-O-Me-cAMP is an agonist of exchange factors activated by cAMP (Epac), while it doesn't activate PKA as cAMP do. 8-Br-2'-O-Me-cAMP can be used in cardiovascular disease research.
    8-Br-2'-O-Me-cAMP
  • HY-143594
    KRAS G12C inhibitor 40
    Inhibitor
    KRAS G12C inhibitor 40 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 40 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 70).
    KRAS G12C inhibitor 40
  • HY-168054
    PROTAC K-Ras Degrader-3
    Degrader
    PROTAC K-Ras Degrader-3 (compound 40) is a PROTAC degrader of K-Ras with a DC50 of ≤ 1 nM against SW620 KRAS G12D, and a GI50 of ≤ 10 nM against SW620 3D cell growth. PROTAC K-Ras Degrader-3 can be utilized in cancer research.
    PROTAC K-Ras Degrader-3
  • HY-152248
    ARS-2102
    Inhibitor
    ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research.
    ARS-2102
  • HY-161635
    SOS1 Ligand intermediate-4
    Inhibitor
    SOS1 Ligand intermediate-4 is a ligand of SOS1, used for the synthesis of PROTAC SOS1 degrader (HY-161634).
    SOS1 Ligand intermediate-4
  • HY-122152
    Spiclomazine hydrochloride
    Inhibitor
    Spiclomazine hydrochloride (APY-606) is an antipsychotic and antitumor agent. Spiclomazine hydrochloride inhibits KRas. Spiclomazine hydrochloride induces cancer cell apoptosis.
    Spiclomazine hydrochloride
  • HY-153880
    KRAS degrader-1
    Degrader
    KRAS degrader-1 (compound 1) is a potent KRAS degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway.
    KRAS degrader-1
  • HY-151999
    KRAS G12C inhibitor 65
    Inhibitor
    KRAS G12C inhibitor 65 is a potent and covalent KRASG12C inhibitor that traps KRASG12C in the GDP-bound state. KRASG12C IN-1 exhibits potent antitumor activity against KRAS-mutant non-small cell lung cancer.
    KRAS G12C inhibitor 65
  • HY-143592
    KRAS G12C inhibitor 39
    Inhibitor
    KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494).
    KRAS G12C inhibitor 39
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.